Drug
Patritumab
Patritumab: highest development phase Phase 1, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Patritumab NCT02350712 | Phase 1 | Squamous Cell Carcinoma of the Head and Neck |
Latest
No recent events.
Follow Patritumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.